nitrosamines – Page 14

Change impact underestimated during post-approval change review – CAPA to prevent repeat failures

Understanding and Managing Change Impact During Post-Approval Review in Pharmaceutical Production In today’s dynamic pharmaceutical landscape, effective management of raw material changes is critical to maintaining compliance and product integrity.…

Change impact underestimated during supplier change – risk-based change impact assessment

Assessing Risks of Supplier Changes: A Tactical Playbook In the dynamic landscape of pharmaceutical manufacturing, the impact of raw material changes can be both underestimated and mismanaged, often leading to…

Unapproved material substitution during supplier change – preventing batch rejection and recalls

Preventing Batch Rejection and Recalls Due to Unapproved Material Substitution In the complex world of pharmaceutical manufacturing, the unapproved substitution of raw materials during a supplier change can lead to…

Change control documentation gaps during deviation investigation – risk-based change impact assessment

Addressing Change Control Documentation Gaps in Deviation Investigations: A Risk-Based Playbook Pharmaceutical manufacturing involves numerous complexities, and deviations can lead to significant operational setbacks. A critical aspect of robust deviation…

Raw material change implemented without assessment during deviation investigation – risk-based change impact assessment

Managing Raw Material Changes Without Prior Assessment During Deviations: An Effective Playbook The pharmaceutical industry faces a multitude of challenges regarding raw material management, particularly when material changes occur without…

Unapproved material substitution during post-approval change review – risk-based change impact assessment

Managing Risks of Unapproved Material Substitution in Post-Approval Changes Unapproved material substitutions during post-approval change reviews pose significant risks in pharmaceutical manufacturing. They can lead to quality deviations, regulatory non-compliance,…

Supplier change not evaluated during deviation investigation – CAPA to prevent repeat failures

Effective Strategies for Evaluating Supplier Changes During Deviation Investigations Changes in suppliers of raw materials can significantly impact the quality and safety of pharmaceutical products. When these changes are not…

Specification change not communicated during routine operations – CAPA to prevent repeat failures

Addressing Uncommunicated Specification Changes during Routine Operations: A Comprehensive CAPA Playbook Specification changes that go uncommunicated during manufacturing operations can lead to significant quality issues, regulatory concerns, and increased operational…

Change impact underestimated during routine operations – regulatory expectations for material changes

Understanding Regulatory Expectations for Material Changes in Routine Operations In the fast-paced environment of pharmaceutical manufacturing, routine operations often pave the way for product quality and compliance. However, the impact…

Nitrosamine Contamination Risk in Raw Materials? Assessment and Control Strategies

Nitrosamine Contamination Challenges in Raw Materials and Control Solutions Nitrosamine contamination poses significant risks to pharmaceutical manufacturing processes, affecting product quality and regulatory compliance. This article addresses the common symptoms…